devast
ebola
viru
ebov
outbreak
west
africa
flag
need
time
develop
vaccin
highthreat
pathogen
better
prepar
new
epidem
compil
list
prioriti
pathogen
like
caus
futur
outbreak
r
effort
therefor
paramount
r
blueprint
http
wwwwhointblueprintprioritydiseasesen
end
detail
character
vaccin
platform
need
vesicular
stomat
viru
vsv
establish
robust
vaccin
vector
backbon
infecti
diseas
well
decad
recent
clinic
trial
test
vaccin
candid
vsvebov
ebov
diseas
ad
substanti
amount
clinic
data
suggest
vsv
ideal
vaccin
vector
candid
outbreak
pathogen
review
discuss
insight
gain
clinic
vsvebov
vaccin
trial
well
anim
studi
investig
vaccin
candid
blueprint
pathogen
articl
histori
emerg
infecti
diseas
major
threat
public
health
ebola
viru
ebov
highthreat
pathogen
recent
declar
one
top
ten
health
threat
world
health
organ
five
public
health
emerg
intern
concern
pheic
declar
date
four
caus
emerg
reemerg
virus
last
year
human
experienc
novel
increasingli
frequent
outbreak
time
effici
countermeasur
lack
peopl
lost
live
dramat
west
african
ebola
viru
diseas
epidem
middl
east
respiratori
syndrom
coronaviru
merscov
demonstr
world
rapidli
viru
spread
new
region
due
travel
korean
man
return
middl
east
infect
merscov
becam
index
case
chain
secondari
mainli
nosocomi
transmiss
cumul
merscov
infect
includ
death
zika
viru
outbreak
america
result
cluster
associ
neurolog
disord
neonat
malform
also
declar
pheic
name
recent
outbreak
emphas
urgenc
creat
strategi
contain
futur
outbreak
fast
effect
futur
socioeconom
factor
includ
increas
global
human
popul
lifespan
urban
intensifi
global
travel
mobil
effect
climat
chang
ripen
condit
emerg
rapid
spread
virus
among
popul
vaccin
effect
way
prevent
control
viral
spread
howev
vaccin
candid
emerg
infect
exist
result
phenomenon
suppli
vacuum
novel
viral
outbreak
ebov
crisi
found
global
medic
commun
illprepar
deploy
prevent
vaccin
delay
due
lack
clinicalstag
vaccin
candid
respons
initi
blueprint
list
prioriti
diseas
acceler
research
develop
effort
pathogen
bear
particularli
high
potenti
caus
epidem
limit
specif
countermeasur
avail
may
therefor
caus
futur
public
health
emerg
r
blueprint
compos
regularli
updat
intern
committe
expert
identifi
defin
prioriti
pathogen
basi
number
criteria
weight
rel
import
major
priorit
criteria
focu
whether
pathogen
transmit
human
extent
medic
countermeasur
avail
sever
casefat
rate
correspond
diseas
factor
potenti
societ
impact
evolutionari
potenti
pathogen
also
taken
account
current
blueprint
review
februari
identifi
present
prioriti
diseas
crimeancongo
hemorrhag
fever
cchf
ebola
viral
diseas
evd
marburg
viral
diseas
mvd
lassa
fever
mer
sever
acut
respiratori
syndrom
sar
nipah
henipavir
diseas
rift
valley
fever
rvf
zika
diseas
well
diseas
x
ayet
unknowndiseas
context
detail
character
assess
vaccin
platform
capabl
appli
swiftli
develop
vaccin
varieti
pathogen
utmost
import
ideal
vaccin
candid
outbreak
scenario
abl
manufactur
rapid
scalabl
fashion
safe
induc
strong
cellular
humor
immun
respons
rapidli
confer
longterm
immun
singl
immun
viral
vector
vaccin
express
varieti
heterolog
antigen
therefor
repres
ideal
vaccin
platform
develop
novel
vaccin
candid
vaccin
candid
base
rhabdovirda
famili
shown
featur
mani
properti
vesicular
stomat
viru
vsv
negativestrand
rna
viru
member
rhabdovirida
famili
consist
simpl
genom
organ
encod
five
structur
protein
nucleoprotein
n
phosphoprotein
p
matrix
glycoprotein
g
rnadepend
rna
polymeras
l
last
decad
recombin
vsv
rvsv
platform
test
multipl
emerg
neglect
viral
diseas
well
therapeut
cancer
vaccin
anim
studi
base
success
establish
method
gener
vsv
dna
rose
et
al
effect
vsv
clone
strategi
implement
multipl
studi
reveal
capac
vsv
express
foreign
antigen
thu
potenti
use
vaccin
candid
benefit
rvsv
platform
includ
review
fast
product
high
titer
propag
almost
mammalian
cell
ii
lack
reassort
correspond
potenti
undergo
genet
shift
vivo
iii
inabl
vector
viral
rna
integr
host
genom
iv
simpl
genet
modif
possibl
accommod
one
multipl
antigen
insert
v
low
seropreval
human
popul
vi
mild
pathogen
human
vii
induct
humor
cellular
immun
respons
commonli
use
vsv
vaccin
design
strategi
util
rvsv
vector
lack
vsvg
modifi
encod
glycoprotein
gp
pathogen
interest
replac
vsvg
express
foreign
gp
viral
membran
besid
effici
stabl
way
insert
antigen
interest
approach
hold
two
major
advantag
serv
attenu
factor
pathogen
wildtyp
vsv
larg
attribut
vsvg
exchang
glycoprotein
may
affect
celltrop
therefor
addit
attenu
vaccin
candid
toxic
pathogen
therebi
significantli
decreas
lead
benign
safeti
profil
simultan
antibodi
respons
wildtyp
vsv
mostli
direct
vsvg
human
therefor
elimin
vsvg
effici
way
significantli
reduc
preexist
vectorspecif
immun
howev
need
consid
rvsv
replic
compet
vector
vulner
popul
includ
immunocompromis
individu
pregnant
women
infant
elderli
may
higher
risk
advers
event
present
review
endeavor
summar
preclin
clinic
data
vsv
vaccin
candid
emerg
infecti
diseas
specif
focu
virus
list
priorit
pathogen
r
blueprint
vsv
vector
vaccin
candid
describ
ebola
marburg
lassa
nipah
zika
cchf
virus
well
mersand
sarscoronavirus
place
particular
emphasi
ebola
vaccin
candid
vsvebov
vaccin
current
advanc
candid
rvsv
platform
one
enter
human
clinic
trial
besid
rvsvvector
hiv
vaccin
candid
oncolyt
vaccin
phase
ebola
viru
ebov
genu
ebolaviru
famili
filovirida
one
six
ebolaviru
speci
sudan
ebolaviru
sudv
forest
ebolaviru
tafv
previous
divoir
ebolaviru
reston
ebolaviru
restv
bundibugyo
ebolaviru
bdbv
newli
discov
bombali
viru
bomv
ebov
etiolog
agent
evd
result
hemorrhag
fever
multiorgan
failur
high
casefat
rate
potenti
threat
pose
ebov
emerg
viru
also
potenti
bioterror
agent
led
first
research
effort
vaccin
candid
ebov
initi
decad
ago
howev
west
african
evd
epidem
declar
pheic
august
th
swift
develop
prevent
vaccin
becam
absolut
prioriti
light
develop
today
clinic
advanc
rvsvvector
vaccin
candidateand
advanc
ebov
vaccin
candid
dateha
enter
clinic
trial
unpreced
pace
vaccin
known
multipl
name
rvsvzebov
vsvebov
reason
uniform
vsvebov
use
refer
vaccin
throughout
review
vsvebov
deriv
chimer
vsv
indiana
strain
vsv
g
replac
transmembran
gp
ebola
viru
formerli
zair
ebolaviru
zebov
design
ebov
deriv
kikwit
strain
vsvebov
first
describ
group
led
heinz
feldmann
ute
stroeher
nation
microbiolog
laboratori
canada
public
health
agenc
object
studi
assess
ebov
gp
pathogen
mice
use
vsv
vector
express
ebov
gp
research
found
inocul
mice
develop
evd
fact
show
symptom
challeng
mouseadapt
ebov
strain
follow
nonhuman
primat
nhp
studi
vaccin
anim
complet
protect
homolog
challeng
subsequ
studi
nhp
provid
evid
toler
efficaci
vaccin
administ
via
sever
rout
administrationor
intranas
intramuscularli
also
receiv
highdos
aerosol
ebov
challeng
furthermor
mice
even
dose
low
two
plaqueform
unit
result
protect
date
vsvebov
describ
immunogen
elicit
high
titer
bind
neutral
antibodi
wide
dose
rang
small
larg
anim
model
well
human
review
monath
et
al
result
phase
clinic
trial
gener
vebcon
vsvebov
consortium
four
independ
yet
harmon
investigatoriniti
trial
switzerland
germani
gabon
kenya
provid
first
safeti
immunogen
assess
vsvebov
human
result
four
phase
trial
unit
state
canada
report
simultan
regul
et
al
nejm
shortli
thereaft
date
total
phase
iiii
clinic
trial
complet
ongo
summar
tabl
vsvebov
furthermor
vaccin
deploy
th
ebov
outbreak
democrat
republ
congo
drc
outbreak
constitut
worst
ebov
outbreak
histori
countri
secondworst
outbreak
global
consequ
recogn
pheic
juli
th
recent
develop
emphas
import
detail
evalu
ampl
preclin
clinic
field
data
vsvebov
gather
date
order
ultim
expedit
licensur
facilit
vaccin
suppli
clinic
trial
variou
dose
level
assess
rang
plaqueform
unit
pfu
pfu
consid
risk
benefit
profil
evalu
human
dosefind
phase
trial
dose
pfu
determin
prefer
dose
consecut
use
phase
ii
iii
trial
well
vaccin
strategi
subsequ
ebov
outbreak
due
high
demand
vaccin
dose
grow
drc
outbreak
consecut
rel
vaccin
shortag
strateg
advisori
group
expert
sage
immun
howev
revis
recommend
current
outbreak
potenc
data
current
deploy
vaccin
lot
show
dosag
reduct
would
averag
still
approxim
concentr
pfu
therefor
reduc
vaccin
dose
recommend
given
highrisk
contact
includ
healthcar
worker
well
contact
contact
confirm
evd
case
addit
vaccin
dose
reduct
recommend
util
wide
ie
broader
popul
evd
case
occur
potenti
prevent
tertiari
evd
case
rapidli
efficaci
data
dosag
howev
need
yet
gener
clinic
trial
vsvebov
administ
intramuscularli
primarili
singleshot
regimena
regimen
previous
shown
protect
soon
administr
nhp
test
singleshot
regimen
indispens
outbreak
situat
especi
volatil
region
insuffici
infrastructur
followup
vaccin
often
possibl
yet
comparison
primeboost
strategi
util
vsvebov
may
benefici
durabl
vaccin
respons
need
expand
first
data
gather
phase
trial
subgroup
individu
receiv
primeboost
regimen
day
vsvebov
three
differ
dose
level
vaccine
develop
higher
antibodi
ab
viru
neutral
titer
compar
particip
receiv
singleshot
yet
observ
longer
statist
signific
six
month
initi
vaccin
primeboost
regimen
evalu
ongo
studi
prevac
studi
present
assess
prime
well
primeboost
regimen
day
vsvebov
comparison
vaccin
strategi
estim
volunt
includ
children
year
age
followup
time
month
anoth
ongo
studi
prepar
studi
investig
immun
respons
durabl
vaccin
efficaci
investig
person
occup
risk
ebov
exposur
healthcar
worker
laboratori
personnel
across
threeyear
timefram
particip
either
vaccin
singl
shot
vsvebov
receiv
booster
immun
month
initi
vaccin
addit
particip
whose
antibodi
level
decreas
beneath
predefin
threshold
also
offer
booster
vaccin
studi
publish
date
differ
wide
across
variabl
size
studi
popul
characterist
dosag
etc
comprehens
conclud
safeti
assess
made
nonetheless
vsvebov
describ
safe
overal
well
toler
also
reactogen
clinic
studi
publish
date
advers
event
document
gener
mild
moder
transient
importantli
vaccinerel
seriou
advers
event
sae
one
case
fever
two
allerg
reaction
one
vaccin
coadminist
amoxicillin
resolv
without
sequelaein
individu
receiv
vaccin
clinic
trial
besid
local
reactogen
report
volunt
frequent
report
advers
event
system
solicit
reaction
headach
report
fever
fatigu
vaccine
publish
phase
iiiii
studi
initi
unexpect
advers
event
constitut
emerg
arthriti
case
test
pcrposit
rvsv
phase
trial
geneva
switzerland
studi
halt
volunt
develop
oligoarthr
receiv
pfu
pfu
vsvebov
ultim
resum
reduc
dose
pfu
arthriti
occur
median
day
vaccin
last
day
develop
arthriti
howev
correl
dosag
individu
receiv
reduc
dose
likewis
develop
arthriti
reduc
dose
cohort
risk
arthriti
furthermor
correl
increas
age
also
observ
develop
correl
higher
vaccin
efficaci
three
affect
particip
also
develop
rvsvpcr
posit
skin
lesion
infecti
rvsv
recov
one
particip
studi
halt
simultan
run
phase
studi
vsvebov
includ
arthralgiaarthr
solicit
advers
event
transient
arthralgia
likewis
report
high
frequenc
arthriti
case
observ
extent
final
arthriti
frequenc
assess
larg
placebocontrol
phase
iii
trial
incid
arthriti
joint
swell
studi
popul
individu
onset
durat
compar
observ
geneva
trial
age
associ
higher
trial
except
util
vaccin
candid
vsvebov
vaccin
given
intramuscular
dose
pfu
singleshot
unless
otherwis
note
trial
number
adapt
monath
et
al
pactr
pan
african
clinic
trial
registri
incid
pronounc
lower
dose
cohort
pfu
vs
pfu
first
emerg
data
small
subset
survey
individu
vaccin
current
evd
outbreak
drc
seem
mirror
safeti
assess
obtain
clinic
trial
advers
event
frequent
arthralgia
rash
report
respect
importantli
vaccin
satisfact
report
high
encourag
find
misconcept
vaccin
evd
constitut
seriou
challeng
healthcar
worker
administ
vaccin
care
current
outbreak
set
besid
assess
advers
event
earli
clinic
studi
also
focus
evalu
potenti
viral
shed
vaccin
individu
via
test
saliva
urin
nhp
model
viral
shed
previous
observ
human
rvsv
viremia
could
detect
earli
vaccin
resolut
day
pv
howev
viral
shed
extrem
rare
present
individu
high
viremia
notabl
children
year
age
less
pronouncedli
adolesc
found
higher
viremia
shed
frequenc
adult
vaccin
pfu
vsvebov
rais
question
whether
lower
vaccin
dose
might
requir
pediatr
popul
vaccin
assess
vulner
popul
import
note
vaccin
safeti
primarili
assess
healthi
adult
pregnant
women
children
howev
disproport
affect
evd
safeti
data
popul
scarc
essenti
small
number
children
includ
clinic
trial
despit
observ
aforement
higher
viremia
total
pediatr
individu
agnandji
colleagu
vaccin
compar
safeti
immunogen
profil
adult
receiv
dose
subsequ
phase
iii
trial
well
vaccin
usag
expand
access
show
accept
safeti
profil
vaccin
children
age
unpublish
ongo
trial
also
includ
children
age
year
san
msf
prevac
trial
hope
provid
data
safeti
efficaci
vsvebov
pediatr
popul
date
pregnant
women
exclud
vsvebov
vaccin
trial
due
safeti
concern
administ
liveattenu
vaccin
vulner
popul
time
mortal
rate
exorbitantli
high
lethal
around
evdaffect
pregnant
women
roughli
unborn
children
pregnant
women
inadvert
receiv
vaccin
case
outcom
publish
date
howev
women
report
pregnanc
within
month
receiv
vaccin
control
phase
iiiii
trial
reassuringli
cohort
pregnanc
loss
occur
often
control
cohort
congenit
anomali
observ
polici
pregnant
women
offer
possibl
receiv
vsvebov
topic
repeat
debat
controversi
msf
among
other
strongli
argu
favor
inclus
pregnant
women
given
enorm
high
probabl
death
infect
view
congoles
ministri
health
back
recent
announc
note
trial
except
util
vaccin
candid
vsvebov
vaccin
given
intramuscular
dose
pfu
singleshot
unless
otherwis
note
trial
number
adapt
monath
et
al
niaid
nation
institut
allergi
infecti
diseas
chang
polici
offer
pregnant
lactat
women
well
children
age
month
contact
identifi
evd
case
vaccin
june
th
vital
protect
popul
also
opportun
gener
data
vaccin
safeti
efficaci
group
great
valu
futur
outbreak
evd
outbreak
occur
popul
high
hiv
incid
rate
import
evalu
safe
vaccin
immunocompromis
individu
vsvebov
report
toler
sever
immunocompromis
nodscid
mice
consecut
test
simianhuman
immunodefici
shiv
model
shiv
infect
macaqu
develop
overt
symptom
fever
vaccin
pfu
vsvebov
dosag
previous
shown
protect
nhp
immunogen
vaccin
limit
ebovgpspecif
antibodi
could
detect
prior
challeng
challeng
lethal
dose
ebov
day
postvaccin
pv
vaccin
anim
show
clinic
sign
ill
two
ultim
die
two
anim
affect
shiv
display
highest
shiv
viremia
lowest
cell
count
group
also
unlik
survivor
show
vsv
viremia
vaccin
studi
underlin
need
assess
vsvebov
immunocompromis
individu
probabl
adapt
vaccin
dosag
schedul
one
phase
ii
trial
vsvebov
date
includ
small
subgroup
hivposit
individu
sae
report
hivposit
particip
within
one
month
vaccin
immunogen
measur
antibodi
respons
found
lower
compar
hivneg
individu
gener
data
larger
cohort
ongo
achiv
phase
ii
trial
specif
examin
safeti
immunogen
vsvebov
estim
hivposit
individu
efficaci
vsvebov
util
outbreak
vsvebov
contain
gp
ebov
kikwit
strain
yet
nhp
model
show
crossprotect
heterolog
west
african
outbreak
strain
ebov
makona
subsequ
phase
iii
trial
ebola
suffit
complet
clinic
trial
report
human
efficaci
data
vsvebov
dateand
trial
report
efficaci
data
evd
vaccin
time
review
studi
conduct
toward
end
west
african
epidem
yield
highli
encourag
result
trial
util
ringvaccin
strategi
cluster
contact
contactsofcontact
around
case
evd
identifi
random
receiv
either
immedi
delay
vaccin
day
durat
one
incub
period
report
ebov
evd
case
day
p
v
assess
studi
report
vaccin
efficaci
random
lift
ring
contact
offer
vaccin
also
includ
children
none
immedi
vaccin
individu
develop
evd
day
post
vaccin
pv
evd
occur
contact
delay
vaccin
cohort
plu
seven
never
vaccin
contact
perfect
efficaci
rate
initi
question
spur
controversi
debat
sinc
trial
design
unblind
number
evd
case
alreadi
decreas
evd
case
report
delay
vaccin
cohort
author
howev
reject
notion
trial
result
bias
due
open
trial
design
basi
efficaci
data
vsvebov
receiv
prioriti
medicin
prime
design
european
medic
associ
ema
well
breakthrough
therapi
design
food
drug
administr
fda
enabl
faster
licensur
process
submiss
roll
licensur
applic
fda
initi
manufactur
merck
novemb
owe
prime
breakthrough
therapi
design
vsvebov
preapprov
emerg
use
outbreak
sage
part
expand
access
framework
also
call
compassion
use
program
pend
licensur
framework
provid
vaccin
consent
atrisk
individu
healthcar
worker
well
ring
contact
outsid
clinic
studi
new
flareup
evd
guinea
march
end
west
african
epidem
declar
framework
util
vaccin
individu
includ
children
age
evd
case
report
vaccin
popul
anoth
peopl
vaccin
ebov
outbreak
drc
may
june
current
ebov
outbreak
drc
declar
august
st
claim
live
human
juli
st
vsvebov
administ
total
time
sinc
initi
vaccin
seven
day
later
addit
msf
also
provid
vaccin
use
ring
vaccin
strategi
assess
vaccin
efficaci
clinic
trial
includ
individu
age
one
trial
reportedli
complet
novemb
clinicaltrialsgov
result
await
great
anticip
meanwhil
recent
report
highli
encourag
preliminari
result
ring
vaccin
regimen
appli
recent
drc
ebov
outbreak
includ
total
vaccin
individu
report
estim
vaccin
efficaci
thu
strongli
support
find
phase
iii
trial
stabil
vaccin
context
deploy
vsvebov
field
set
storag
vaccin
must
kept
temperatur
maximum
remain
challeng
establish
mainten
cold
chain
often
rural
surround
suboptim
infrastructur
difficult
date
stabil
data
remain
scarc
yet
one
studi
found
vaccin
stay
stabl
compar
viral
titer
day
store
guineapig
challeng
model
vaccin
vsvebov
confer
protect
diseas
even
store
variou
suboptim
condit
day
room
temperatur
three
cycl
freezethaw
room
temperatur
vaccin
kept
show
signific
reduct
viru
titer
data
indic
shortterm
interrupt
cold
chain
may
toler
without
affect
vaccin
efficaci
understand
correl
protect
evd
remain
challeng
still
biomark
associ
ebov
vaccin
efficaci
identif
ebovassoci
correl
protect
challeng
marker
defin
ebov
incid
suffici
high
outbreak
ebola
suffit
trial
provid
strong
evid
high
protect
vsvebov
blood
sampl
analyz
immunogen
protect
marker
could
gener
trial
first
insight
possibl
correl
protect
provid
assess
immun
respons
survivor
fatal
case
ebovinfect
individu
follow
west
african
evd
epidem
one
studi
demonstr
fatal
case
associ
increas
express
exhaust
marker
cell
transcriptom
analysi
blood
rna
ebovinfect
patient
show
elev
express
level
gene
associ
interferon
acut
phase
signal
pathway
lower
level
inflamm
correl
viru
clearanc
robust
ebovspecif
tcell
respons
although
novel
data
provid
insight
innat
adapt
immun
respons
contribut
protect
human
still
defin
notabl
correl
protect
may
differ
natur
evd
infect
vaccineinduc
immun
respons
studi
compar
immun
respons
evd
survivor
current
ongo
florian
klein
person
commun
anim
model
crucial
deciph
immun
respons
mechan
import
protect
past
guinea
pig
well
nonhumanprim
ebov
model
use
unravel
protect
mechan
andrea
marzi
colleagu
comprehens
analyz
ebov
challeng
cynomolgu
macaqu
vaccin
deplet
method
cell
well
bcell
block
reveal
critic
role
ebov
gpspecif
antibodi
pivot
role
vsvebovinduc
innat
immun
confer
earli
antivir
control
gener
effect
humor
immun
respons
demonstr
nhp
challeng
model
transcript
whole
blood
profil
vaccin
anim
challeng
differ
timepoint
day
pv
uncov
gene
associ
antivir
innat
respons
upregul
earli
timepoint
delay
anim
surviv
challeng
day
pv
collect
sampl
obtain
west
african
epidem
ongo
outbreak
drc
togeth
numer
individu
vaccin
vsvebov
gener
highli
valuabl
bodi
inform
fill
critic
knowledg
gap
regard
mechan
crucial
immun
protect
first
metaanalysi
publish
gross
colleagu
summar
antibodi
respons
clinic
trial
vsvebov
test
studi
observ
induct
ebov
gpspecif
antibodi
respons
follow
immun
vsv
antibodi
respons
develop
day
pv
peak
around
day
remain
detect
least
year
besid
evalu
humor
respons
clinic
trial
also
evalu
arm
immun
respons
one
studi
focus
follicular
helper
tfh
cell
observ
correl
antibodi
titer
cellular
immun
respons
observ
cohort
receiv
dose
pfu
ebov
gp
specif
tcell
secret
mainli
lower
dose
group
show
antigenspecif
tcell
respons
recent
advanc
understand
innat
immun
system
use
system
biolog
approach
begin
reveal
fundament
mechan
innat
immun
system
orchestr
protect
immun
respons
vaccin
investig
innat
immun
respons
follow
vsvebov
immun
data
reveal
innat
immun
signatur
correl
antibodi
respons
hamburg
vsvebov
vaccin
trial
addit
chang
express
level
circul
mirna
associ
increas
ebov
gpspecif
antibodi
titer
furthermor
innat
immun
signatur
assess
vaccine
europ
africa
reveal
earli
induct
day
pv
chemokin
cytokin
associ
monocyt
function
comprehens
evalu
immunogen
follow
vsvebov
vaccin
still
ongo
system
vaccinolog
approach
clinic
immunolog
transcriptom
metabolom
data
clinic
vaccin
studi
integr
analyz
data
survivor
instrument
identifi
ebov
vaccin
correl
protect
experi
use
postexposur
prophylaxi
vsvebov
intend
use
prophylact
vaccin
howev
implement
postexposur
prophylaxi
intrigu
swift
identif
vaccin
evdaffect
individualsif
effectivewould
contribut
time
contain
futur
outbreak
nhp
vsvebov
fulli
protect
given
day
challeng
amelior
diseas
given
day
preexposur
mice
vaccin
vsvebov
h
postinfect
pi
confer
complet
protect
guinea
pig
show
partial
protect
challeng
vaccin
h
preto
h
postexposur
lastli
nhp
protect
confer
anim
vaccin
postexposur
line
find
separ
studi
describ
overal
protect
evd
nhp
vaccin
either
h
h
pi
vaccin
twice
h
h
pi
half
vaccin
dose
respect
surprisingli
howev
postexposur
prophylaxi
rvsvvector
vaccin
marburg
viru
confer
similar
protect
evd
author
argu
vsvdriven
innat
immun
activ
well
filovirusspecif
immun
respons
may
play
role
protect
evd
note
compar
diseas
cours
human
onset
clinic
diseas
faster
manifest
sever
nhp
model
lethal
close
nhp
challeng
sudan
ebolaviru
sudv
lead
lethal
diseas
nhp
later
ebov
nhp
protect
vaccin
rvsvsudv
min
pi
efficaci
postexposur
prophylaxi
may
thu
well
higher
human
nhp
model
human
vsvebov
first
use
emerg
postexposur
vaccin
long
enter
clinic
trial
use
total
seven
individu
occup
exposur
ebov
vaccin
administ
h
day
postexposur
none
individu
develop
evd
cours
unknown
whether
extent
postexposur
prophylaxi
prevent
develop
evd
albeit
case
report
anecdot
natur
encourag
provid
basi
current
evd
postexposur
recommend
vectorspecif
immun
although
preexist
antivsv
immun
rare
found
human
antivector
immun
vaccin
vsv
vector
vaccin
might
impair
vaccin
efficaci
futur
vsvbase
vaccin
primeboost
regimen
data
investig
preexist
immun
remain
scarc
recent
demonstr
vaccin
vsvebov
induc
vectorspecif
humor
cellular
immun
respons
vsvspecif
antibodi
respons
gener
human
studi
follow
vaccin
vsvebov
nonneutr
correl
ebov
gpspecif
antibodi
respons
regard
potenti
simultan
use
vsvebov
vsvbase
lassa
viru
lasv
vaccin
west
africa
marzi
et
al
vaccin
cynomolgu
macaqu
vsvebov
day
receiv
protect
dose
lassa
vaccin
lasvgpc
despit
signific
antivsv
antibodi
titer
vaccin
vsvebov
vaccin
confer
full
protect
ebov
challeng
suggest
repeat
vaccin
vsvvector
vaccin
may
efficaci
clinic
trial
vsvebov
still
ongo
effort
creat
attenu
secondgener
rvsvebov
vaccin
alreadi
underway
goal
reduc
reactogen
maintain
immunogen
one
approach
vsv
gp
substitut
ebov
gp
exhibit
mutat
impair
cell
entri
vsv
ebovgp
induc
immunogen
guinea
pig
compar
vaccin
rvsv
express
propagationcompet
ebov
gp
howev
vaccin
construct
found
genet
unstabl
quickli
revert
back
infecti
variant
passag
mutat
may
therefor
introduc
order
maintain
propag
restrict
anoth
attenu
rvsvebov
vaccin
candid
rvsv
vector
attenu
combin
transloc
n
protein
posit
truncat
vsvg
cytoplasmat
tail
ct
express
ebov
gp
ebovmayinga
strain
first
posit
rvsv
genom
vector
previous
test
hiv
vaccin
candid
phase
clinic
trial
well
toler
vaccin
mice
develop
humor
cellular
immun
respons
guinea
pig
macaqu
complet
protect
ebov
challeng
mount
antibodi
respons
latter
day
pv
importantli
vaccin
primat
also
protect
heterolog
challeng
ebovmakona
licens
profectu
bioscienc
biotech
compani
special
vaccin
develop
use
attenu
rvsv
vector
number
vaccin
candid
evalu
phase
doseescal
trial
marburg
hemorrhag
fever
caus
marburg
viru
marv
genu
marburgviru
character
high
casefat
rate
also
belong
famili
filovirida
marv
share
lot
characterist
ebov
howev
histor
less
frequent
outbreak
fewer
affect
individu
occur
pose
great
potenti
public
health
threat
emerg
viru
list
categori
bioterror
agent
center
diseas
control
cdc
make
vaccin
develop
prioriti
despit
decad
research
licens
vaccin
therapi
avail
date
howev
ampl
preclin
data
rvsvvector
marv
vaccin
candid
generatedoften
alongsid
ebov
vaccin
candid
preexposur
prophylact
well
postexposur
vaccin
review
analog
ebov
counterpart
rvsvmarv
vaccin
candid
util
immunogen
marv
gp
shown
toler
well
efficaci
variou
anim
model
includ
nhp
model
prevent
vaccin
marvgp
use
gp
strain
musok
express
antigen
shown
complet
protect
cynomolgu
macaqu
day
pv
lethal
marv
challeng
even
challeng
almost
month
initi
vaccin
differ
marv
strain
popp
subsequ
studi
demonstr
vaccin
capabl
confer
crossprotect
nhp
challeng
virul
strain
angola
well
genet
distant
ravn
strain
amino
acid
deviat
around
studi
dose
pfu
administ
high
antimarv
igg
titer
develop
rvsv
viremia
detect
around
day
pv
close
mirror
observ
made
vsvebov
primat
develop
sign
clinic
ill
abnorm
hematolog
blood
chemistri
valu
periand
postexposur
prophylaxi
efficaci
evalu
anim
model
vaccin
min
pi
fulli
protect
rhesu
macaqu
homolog
challeng
ld
dose
marv
administr
h
h
postexposur
protect
macaqu
respect
suggest
efficacyalbeit
limiteda
postexposur
treatment
even
high
exposur
dose
contrast
two
vaccin
candid
express
marvangola
gp
test
postexposur
efficaci
min
homolog
marv
challeng
surviv
rate
depend
challeng
dosag
attenu
vector
use
probabl
due
higher
pathogen
well
shorter
incub
period
marvangola
variant
high
clinic
import
marvangola
strain
respons
worst
outbreak
marburg
hemorrhag
fever
far
notabl
surviv
anim
mount
antimarv
specif
igg
antibodi
respons
day
indic
postexposur
treatment
may
confer
protect
delay
diseas
progress
long
enough
infect
subject
develop
suffici
immun
durabl
postvaccin
immun
furthermor
assess
monthli
measur
antimarvgp
antibodi
initi
vaccin
macaqu
anim
develop
strong
humor
respons
remain
overal
stabl
cours
month
macaqu
challeng
homolog
marvmusok
anim
develop
clinic
sign
ill
demonstr
efficaci
vaccin
least
year
taken
togeth
data
studi
strong
protect
capac
rvsvmarv
seem
primarili
mediat
strong
humor
immun
respons
combin
rvsvvector
filoviru
vaccin
largest
evd
outbreak
date
caus
ebov
evd
outbreak
caus
ebolaviru
speci
also
describ
marv
ebov
outbreak
occur
overlap
geograph
region
crossprotect
vsvebov
marv
heterolog
strain
demonstr
outlin
howev
limit
crossprotect
might
exist
distantli
relat
speci
genera
therefor
combin
rvsvvector
filoviru
vaccin
would
desir
evalu
vaccin
multicompon
vaccin
consist
marvand
sudvgp
macaqu
surviv
challeng
either
respect
speci
tafv
monkey
challeng
marv
ebov
tafv
show
clinic
sign
diseas
challeng
sudv
author
argu
observ
could
due
slower
replic
kinet
differenti
affin
gp
antigenpres
cell
therefor
test
twostag
vaccin
administ
two
week
prior
vaccin
marv
result
complet
protect
challeng
clinic
evid
infect
challeng
sudv
subsequ
back
challeng
marv
anoth
studi
vector
express
either
ebov
sudv
marv
gp
first
posit
rvsv
genom
administ
macaqu
trival
vaccin
none
anim
succumb
diseas
challeng
pathogen
howev
subset
vaccin
macaqu
develop
mild
sign
diseas
well
low
level
filoviru
viremia
especi
challeng
ebov
attenu
vector
use
vector
current
employ
effort
develop
multival
vaccin
candid
marv
sudv
ebov
addit
lassa
viru
arenaviru
lasv
one
primari
causal
agent
hemorrhag
fever
worldwid
estim
infect
record
annual
west
africa
endem
rodenttransmit
diseas
diseas
cours
highli
divers
depend
lasv
clade
morbid
signific
sinc
januari
nigeria
face
ongo
outbreak
lassa
fever
confirm
case
lasv
infect
death
casefat
rate
nigeria
center
diseas
control
ncdc
march
due
widespread
geograph
distribut
high
incid
lack
prevent
vaccin
approv
therapi
lasv
identifi
emerg
viru
r
effort
given
high
prioriti
multipl
intern
profession
organ
includ
coalit
epidem
prepared
innov
cepi
analog
rvsv
vector
express
marv
ebov
gp
dr
feldmann
stroeher
describ
lasv
glycoprotein
c
gpc
express
rvsv
clade
iv
isol
josiah
detect
pathogen
mice
nhp
model
relev
anim
model
lasv
infect
efficaci
vaccin
dose
pfu
assess
macaqu
n
well
toler
viral
shed
occur
vaccin
hematolog
blood
chemistri
analysi
found
slight
thrombocyt
decreas
well
slight
elev
alt
anim
anim
remain
asymptomat
lethal
lasv
challeng
day
vaccin
contrast
control
succumb
infect
high
lasvspecif
antibodi
titer
well
moder
tcell
respons
could
detect
immun
steril
anim
develop
viremia
clear
day
viremia
howev
observ
consecut
experi
anoth
vaccin
construct
vsv
express
lasv
nucleoprotein
np
meanwhil
show
limit
protect
pursu
genet
heterogen
observ
lasv
clade
rais
concern
whether
act
univers
vaccin
question
examin
subsequ
studi
inbr
guinea
pig
well
nhp
vaccin
result
full
protect
homolog
challeng
well
challeng
heterolog
lasv
clade
iv
isol
day
pv
challeng
inbr
guinea
pig
clade
isol
pinneo
one
genet
diverg
isol
compar
josiah
result
clinic
diseas
note
anim
vaccin
irrelev
control
vector
develop
symptomat
diseas
abl
clear
infect
work
elucid
lassa
crossclad
immun
current
ongo
better
understand
durabl
lasvgpc
need
estim
potenti
benefit
vaccin
candid
stein
colleagu
therefor
sought
examin
earli
long
confer
protect
guinea
pigadapt
gpa
lasv
model
anim
vaccin
pfu
lasvgpc
challeng
timepoint
day
pv
earli
day
pv
vaccin
provid
full
protect
clinic
diseas
howev
immun
steril
antibodi
respons
peak
day
sustain
final
sampl
date
one
year
later
challeng
pv
guinea
pig
develop
sign
diseas
anim
still
protect
death
recent
develop
cepi
furthermor
award
consider
research
fund
develop
manufactur
ultim
stockpil
lassa
viru
vaccin
base
mention
platform
research
includ
addit
studi
nhp
warrant
data
suggest
may
univers
vaccin
candid
confer
earli
last
immun
base
promis
result
obtain
studi
rvsv
vaccin
candid
express
filoand
arenaviru
gp
replicationcompet
rvsv
express
glycoprotein
precursor
gpc
cchfv
likewis
hemorrhag
fever
viru
recent
develop
test
immunocompromis
knockout
mous
model
studi
primeonli
primeboost
regimen
day
compar
mock
vaccin
immunogen
well
protect
challeng
cchfv
day
prime
vaccin
assess
group
receiv
either
one
two
inject
develop
cchfvgp
bind
well
viru
neutral
antibodi
primeboost
group
show
milder
sign
infect
anim
primeonli
primeboost
group
surviv
challeng
none
mockvaccin
henipaviru
nipah
viru
niv
zoonot
pathogen
caus
sever
pulmonari
neurolog
diseas
high
casefat
rate
respons
almost
yearli
outbreak
indian
subcontin
niv
vaccin
portfolio
current
develop
includ
rvsvvector
nipah
vaccin
util
rvsv
express
two
differ
structur
protein
antigen
niv
fusion
f
attach
g
glycoproteinstwo
surfac
protein
togeth
requir
viral
cell
entri
rvsv
vector
express
either
antigen
describ
two
differ
model
one
insert
either
protein
vsvg
vsvgf
niv
place
vsv
glycoprotein
niv
mice
intranas
administr
rvsvg
niv
andor
f
niv
induc
neutral
ab
nab
format
highest
nab
format
observ
rvsvg
niv
alon
combin
rvsvf
niv
given
vector
evalu
use
im
vaccin
likewis
induc
nab
especi
f
niv
use
combin
note
combin
administr
niv
found
lethal
given
intranas
postnat
mice
later
studi
individu
administr
either
vaccin
candid
caus
symptom
even
directli
inject
brain
vaccin
f
niv
demonstr
fulli
protect
niv
challeng
syrian
hamster
model
none
anim
develop
diseas
similarli
vector
vsvebov
complement
niv
f
g
protein
downstream
ebovgp
assess
hamster
model
confer
level
protect
diseas
importantli
vaccin
administ
day
prior
challeng
studi
followup
studi
addit
demonstr
periexposur
protect
full
protect
achiev
one
day
vaccin
decreas
one
day
challeng
administr
three
day
challeng
show
protect
interestingli
similarli
observ
made
marzi
et
al
ebov
postexposur
vaccin
model
rvsv
vector
vaccin
control
also
mediat
partial
protect
given
one
day
prechalleng
antibodi
gener
associ
protect
serumtransf
experi
confirm
protect
antibodydepend
simultan
assess
vector
express
niv
nucleocapsid
protein
n
shown
inferior
f
g
variant
immunogen
niv
subsequ
demonstr
complet
protect
african
green
monkey
describ
appropri
anim
model
niv
infect
mersand
sarscoronavirus
sar
well
mer
constitut
sever
pulmonari
infect
caus
sarsand
merscoronavirus
cov
respect
sever
outbreak
sarscov
origin
china
spread
swiftli
ultim
affect
human
within
month
viru
contain
potenti
reemerg
caus
new
outbreak
remain
high
rvsv
platform
employ
creat
sarscov
vaccin
candid
futur
scenario
vsv
express
immunogen
spike
protein
sarscov
g
l
gene
vsv
mous
model
vaccin
vsv
induc
higher
level
neutral
antibodi
immun
sarscov
confer
protect
measur
low
undetect
sarscov
viral
load
respiratori
tract
even
challeng
month
p
v
use
antisera
vsv
vaccin
mice
mice
could
shown
protect
effect
mediat
antibodi
vaccin
candid
attenu
replac
vsv
g
sarscov
result
immunogen
replicationdefect
vector
surprisingli
greater
immunogen
vsv
appli
im
effect
author
argu
could
due
higher
express
sarscov
protein
among
other
analog
manner
later
use
creat
merscov
vaccin
express
merscov
spike
protein
display
immunogen
rhesu
monkey
date
human
clinic
trial
report
vsvbase
cov
vaccin
roadmap
merscov
research
product
develop
current
includ
rvsvvector
vaccin
portfolio
vector
vaccin
zika
viru
rvsv
vector
also
employ
design
vaccin
candid
zika
viru
zikv
flaviviru
close
relat
dengu
westnil
japanes
enceph
yellow
fever
virus
associ
sever
neurolog
disord
microcephali
newborn
syndrom
spread
zikv
infect
receiv
attent
rapidli
dissemin
brazil
throughout
america
autochthon
case
zikv
infect
describ
rvsv
vaccin
vector
express
divers
zikv
antigen
describ
proofofconcept
studi
rvsv
vector
entail
mutat
protein
attenu
factor
vsvm
express
either
zika
envelop
zenv
alon
zenv
contain
precursor
membran
prm
protein
zprme
describ
construct
remain
replic
compet
mice
vaccin
trigger
overt
patholog
vsvmzprme
vaccin
induc
neutral
antibodi
titer
zikv
infect
lead
diseas
adult
mice
challeng
studi
perform
offspr
vaccin
mother
therefor
statement
efficaci
vaccin
limit
anoth
approach
attenu
vsvebov
use
vector
express
zprme
prm
solubl
envelop
protein
antigen
zprmsole
efficaci
test
type
interferon
receptor
defici
mice
ifnar
zikv
vaccin
candid
result
pathogen
mice
howev
unexpectedli
vaccin
vsvebov
control
vector
led
sever
clinic
symptom
immunocompromis
mice
thu
vsvebovbas
zikv
vaccin
construct
appear
attenu
origin
vsvebov
studi
mice
challeng
zikv
day
pv
fulli
protect
diseas
antigen
zprme
seem
superior
zprmsole
protect
achiev
mice
vaccin
rvsvzprme
day
prechalleng
respect
interestingli
vaccin
vaccin
suffici
also
protect
outbr
mice
ebov
challeng
studi
assess
multipl
zikv
antigen
vsv
vector
attenu
via
point
mutat
vsv
l
protein
combin
zikv
prm
e
protein
nonstructur
protein
show
robust
humor
cellular
respons
immunocompet
mice
well
protect
diseas
ifnar
mice
furthermor
vsv
vector
express
zikv
capsid
protein
also
shown
immunogen
domin
cellular
immun
respons
reduc
viral
replic
spinal
cord
brain
tissu
immunocompet
mice
human
clinic
trial
use
vsvbase
zikv
vaccin
candid
initi
date
rvsv
vaccin
platform
exhibit
mani
advantag
vaccin
vector
backbon
express
viral
antigen
test
vaccin
candid
multitud
emerg
infect
result
recent
clinic
phase
iiii
trial
vsvebov
gain
signific
amount
data
human
encouragingli
suggest
favor
safeti
profil
vaccin
candid
well
swift
protect
singl
immun
vsv
readili
attenu
remain
immunogen
comprehens
detail
vsv
vaccinemedi
protect
immun
yet
elucid
data
gener
date
support
premis
protect
appear
primarili
infer
antibodi
respons
howev
cellular
immun
simultan
induc
addit
fact
recombin
manufactur
quickli
divers
antigen
add
valu
vaccin
platform
outbreak
pathogen
focus
blueprint
prioriti
pathogen
varieti
vsvbase
vaccin
candid
describ
emerg
reemerg
pathogen
includ
enteroviru
chikungunya
westnil
sever
fever
thrombocytopenia
syndrom
and
virus
anim
studi
vsvbase
vector
vaccin
marv
lasv
niv
zikv
mersand
sarscov
describ
yield
promis
result
progress
rvsv
vaccin
candid
clinic
trial
may
add
portfolio
effect
outbreak
vaccin
forese
futur
